|
1
|
Bartram CR, de Klein A, Hagemeijer A, van
Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G,
Ferguson-Smith MA, Davies T, Stone M, et al: Translocation of c-ab1
oncogene correlates with the presence of a Philadelphia chromosome
in chronic myelocytic leukaemia. Nature. 306:277–280. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Faderl S, Talpaz M, Estrov Z, O’Brien S,
Kurzrock R and Kantarjian HM: The biology of chronic myeloid
leukemia. N Engl J Med. 341:164–172. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldman JM and Melo JV: Chronic myeloid
leukemia--advances in biology and new approaches to treatment. N
Engl J Med. 349:1451–1464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kantarjian HM, Kurzrock R and Talpaz M:
Philadelphia chromosome-negative chronic myelogenous leukemia and
chronic myelomonocytic leukemia. Hematol Oncol Clin North Am.
4:389–404. 1990.PubMed/NCBI
|
|
5
|
Martiat P, Michaux JL and Rodhain J:
Philadelphia-negative (Ph-) chronic myeloid leukemia (CML):
Comparison with Ph+ CML and chronic myelomonocytic leukemia. The
Groupe Français de Cytogénétique Hématologique. Blood. 78:205–211.
1991.PubMed/NCBI
|
|
6
|
Santucci MA, Saglio G and Tura S:
Pathogenesis and progression of chronic myeloid leukemia.
Haematologica. 81:63–76. 1996.PubMed/NCBI
|
|
7
|
Goldman JM: Chronic myeloid leukemia: A
historical perspective. Semin Hematol. 47:302–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kantarjian HM, O’Brien S, Smith TL, Rios
MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S,
et al: Treatment of Philadelphia chromosome-positive early chronic
phase chronic myelogenous leukemia with daily doses of interferon
alpha and low-dose cytarabine. J Clin Oncol. 17:284–292.
1999.PubMed/NCBI
|
|
9
|
Druker BJ, Sawyers CL, Kantarjian H, Resta
DJ, Reese SF, Ford JM, Capdeville R and Talpaz M: Activity of a
specific inhibitor of the BCR-ABL tyrosine kinase in the blast
crisis of chronic myeloid leukemia and acute lymphoblastic leukemia
with the Philadelphia chromosome. N Engl J Med. 344:1038–1042.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gambacorti-Passerini C, le Coutre P,
Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi
A, Corneo GM, Belotti D, et al: Inhibition of the ABL kinase
activity blocks the proliferation of BCR/ABL+ leukemic
cells and induces apoptosis. Blood Cells Mol Dis. 23:380–394. 1997.
View Article : Google Scholar
|
|
11
|
Kantarjian HM, Cortes JE, O’Brien S, Giles
F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L,
et al: Imatinib mesylate therapy in newly diagnosed patients with
Philadelphia chromosome-positive chronic myelogenous leukemia: High
incidence of early complete and major cytogenetic responses. Blood.
101:97–100. 2003. View Article : Google Scholar
|
|
12
|
Kantarjian H, Talpaz M, O’Brien S,
Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L,
Thomas D, et al: High-dose imatinib mesylate therapy in newly
diagnosed Philadelphia chromosome-positive chronic phase chronic
myeloid leukemia. Blood. 103:2873–2878. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hughes TP and Branford S: Monitoring
disease response to tyrosine kinase inhibitor therapy in CML.
Hematology Am Soc Hematol Educ Program. 2009.477–487.
2009.PubMed/NCBI
|
|
14
|
Alaiya AA1, Franzén B, Hagman A, Dysvik B,
Roblick UJ, Becker S, Moberger B, Auer G and Linder S: Molecular
classification of borderline ovarian tumors using hierarchical
cluster analysis of protein expression profiles. Int J Cancer.
98:895–899. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alaiya AA, Franzén B, Hagman A,
Silfverswärd C, Moberger B, Linder S and Auer G: Classification of
human ovarian tumors using multivariate data analysis of
polypeptide expression patterns. Int J Cancer. 86:731–736. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alaiya A, Fox J, Bobis S, Matic G,
Shinwari Z, Barhoush E, Márquez M, Nilsson S and Holmberg AR:
Proteomic analysis of soft tissue tumor implants treated with a
novel polybisphosphonate. Cancer Genomics Proteomics. 11:39–49.
2014.PubMed/NCBI
|
|
17
|
Al-Moghrabi N, Nofel A, Al-Yousef N,
Madkhali S, Bin Amer SM, Alaiya A, Shinwari Z, Al-Tweigeri T,
Karakas B, Tulbah A, et al: The molecular significance of
methylated BRCA1 promoter in white blood cells of cancer-free
females. BMC Cancer. 14:8302014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li GZ, Vissers JP, Silva JC, Golick D,
Gorenstein MV and Geromanos SJ: Database searching and accounting
of multiplexed precursor and product ion spectra from the data
independent analysis of simple and complex peptide mixtures.
Proteomics. 9:1696–1719. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nowicki MO, Pawlowski P, Fischer T, Hess
G, Pawlowski T and Skorski T: Chronic myelogenous leukemia
molecular signature. Oncogene. 22:3952–3963. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alaiya A, Al-Mohanna M and Linder S:
Clinical cancer proteomics: Promises and pitfalls. J Proteome Res.
4:1213–1222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Celis JE: Gel-based proteomics: What does
MCP expect? Mol Cell Proteomics. 3:9492004.PubMed/NCBI
|
|
22
|
Celis JE and Gromov P: High-resolution
two-dimensional gel electrophoresis and protein identification
using western blotting and ECL detection. EXS. 88:55–67.
2000.PubMed/NCBI
|
|
23
|
Alaiya AA, Franzén B, Fujioka K, Moberger
B, Schedvins K, Silfversvärd C, Linder S and Auer G: Phenotypic
analysis of ovarian carcinoma: polypeptide expression in benign,
borderline and malignant tumors. Int J Cancer. 73:678–683. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alaiya AA, Franzén B, Moberger B,
Silfverswärd C, Linder S and Auer G: Two-dimensional gel analysis
of protein expression in ovarian tumors shows a low degree of
intratumoral heterogeneity. Electrophoresis. 20:1039–1046. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Erler BS, Hsu L, Truong HM, Petrovic LM,
Kim SS, Huh MH, Ferrell LD, Thung SN, Geller SA and Marchevsky AM:
Image analysis and diagnostic classification of hepatocellular
carcinoma using neural networks and multivariate discriminant
functions. Lab Invest. 71:446–451. 1994.PubMed/NCBI
|
|
26
|
Goldschmidt D, Decaestecker C, Berthe JV,
Gordower L, Remmelink M, Danguy A, Pasteels JL, Salmon I and Kiss
R: The contribution of image cytometry and artificial
intelligence-related methods of numerical data analysis for adipose
tumor histopathologic classification. Lab Invest. 75:295–306.
1996.PubMed/NCBI
|
|
27
|
Ravdin PM, Clark GM, Hilsenbeck SG, Owens
MA, Vendely P, Pandian MR and McGuire WL: A demonstration that
breast cancer recurrence can be predicted by neural network
analysis. Breast Cancer Res Treat. 21:47–53. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tewari A and Narayan P: Novel staging tool
for localized prostate cancer: A pilot study using genetic adaptive
neural networks. J Urol. 160:430–436. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Albano F, Zagaria A, Anelli L, Coccaro N,
Impera L, Minervini CF, Minervini A, Rossi AR, Tota G, Casieri P,
et al: Gene expression profiling of chronic myeloid leukemia with
variant t(9;22) reveals a different signature from cases with
classic translocation. Mol Cancer. 12:362013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Verhaak RG, Wouters BJ, Erpelinck CA,
Abbas S, Beverloo HB, Lugthart S, Löwenberg B, Delwel R and Valk
PJ: Prediction of molecular subtypes in acute myeloid leukemia
based on gene expression profiling. Haematologica. 94:131–134.
2009. View Article : Google Scholar :
|
|
31
|
Alsagaby SA, Khanna S, Hart KW, Pratt G,
Fegan C, Pepper C, Brewis IA and Brennan P: Proteomics-based
strategies to identify proteins relevant to chronic lymphocytic
leukemia. J Proteome Res. 13:5051–5062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pizzatti L, Panis C, Lemos G, Rocha M,
Cecchini R, Souza GH and Abdelhay E: Label-free MSE proteomic
analysis of chronic myeloid leukemia bone marrow plasma: Disclosing
new insights from therapy resistance. Proteomics. 12:2618–2631.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gjertsen BT and Wiig H: Investigation of
therapy resistance mechanisms in myeloid leukemia by protein
profiling of bone marrow extracellular fluid. Expert Rev
Proteomics. 9:595–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Linger RM, Keating AK, Earp HS and Graham
DK: TAM receptor tyrosine kinases: Biologic functions, signaling,
and potential therapeutic targeting in human cancer. Adv Cancer
Res. 100:35–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun WS, Fujimoto J and Tamaya T: Clinical
implications of coexpression of growth arrest-specific gene 6 and
receptor tyrosine kinases Axl and Sky in human uterine leiomyoma.
Mol Hum Reprod. 9:701–707. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu S, Wurdak H, Wang Y, Galkin A, Tao H,
Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, et al: A genomic
screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl
Acad Sci USA. 106:17025–17030. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kerkhoff C, Klempt M and Sorg C: Novel
insights into structure and function of MRP8 (S100A8) and MRP14
(S100A9). Biochim Biophys Acta. 1448:200–211. 1998. View Article : Google Scholar
|
|
38
|
Thomas CG, Patel RM and Bergfeld WF:
Cytophagic and S-100 protein immunoreactive myeloid leukemia cutis.
J Cutan Pathol. 37:390–395. 2010. View Article : Google Scholar
|
|
39
|
Ng CS, Lam TK, Chan JK, Hui PK, Ng HK,
Szeto SC and Feng CS: Juvenile chronic myeloid leukemia. A
malignancy of S-100 protein-positive histiocytes. Am J Clin Pathol.
90:575–582. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gómez-Casares MT, García-Alegria E,
López-Jorge CE, Ferrándiz N, Blanco R, Alvarez S, Vaqué JP,
Bretones G, Caraballo JM, Sánchez-Bailón P, et al: MYC antagonizes
the differentiation induced by imatinib in chronic myeloid leukemia
cells through downregulation of p27KIP1. Oncogene.
32:2239–2246. 2013. View Article : Google Scholar
|
|
41
|
Vaqué JP, Navascues J, Shiio Y, Laiho M,
Ajenjo N, Mauleon I, Matallanas D, Crespo P and León J: Myc
antagonizes Ras-mediated growth arrest in leukemia cells through
the inhibition of the Ras-ERK-p21Cip1 pathway. J Biol
Chem. 280:1112–1122. 2005. View Article : Google Scholar
|
